A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Cardiovascular complications account for the majority of deaths caused by diabetes mellitus. Platelet hyperactivity has been shown to increase the risk of thrombotic events and is a therapeutic target for their prevention in diabetes. Modulation of platelet function by diabetes agents in addition to their hypoglycemic effects would contribute to cardiovascular protection. Newly introduced antidiabetic drugs of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors may have anti-platelet effects, and in the case of SGLT2i and GLP-1RA may contribute to their proven cardiovascular benefit that has been shown clinically.
OBJECTIVE: Here, we reviewed the potential effects of these agents on platelet function in diabetes.
RESULTS AND CONCLUSION: GLP-1RA and DPP-4i drugs have antiplatelet properties beyond their primary hypoglycemic effects. Whilst we have little direct evidence for the antiplatelet effects of SGLT2 inhibitors, some studies have shown that these agents may inhibit platelet aggregation and reduce the risk of thrombotic events in diabetes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Endocrine, metabolic & immune disorders drug targets - 20(2020), 3 vom: 26., Seite 328-334 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yaribeygi, Habib [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.01.2021 Date Revised 01.01.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871530319666191014110414 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302195092 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302195092 | ||
| 003 | DE-627 | ||
| 005 | 20231225110217.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871530319666191014110414 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1007.xml |
| 035 | |a (DE-627)NLM302195092 | ||
| 035 | |a (NLM)31612835 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yaribeygi, Habib |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.01.2021 | ||
| 500 | |a Date Revised 01.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Cardiovascular complications account for the majority of deaths caused by diabetes mellitus. Platelet hyperactivity has been shown to increase the risk of thrombotic events and is a therapeutic target for their prevention in diabetes. Modulation of platelet function by diabetes agents in addition to their hypoglycemic effects would contribute to cardiovascular protection. Newly introduced antidiabetic drugs of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors may have anti-platelet effects, and in the case of SGLT2i and GLP-1RA may contribute to their proven cardiovascular benefit that has been shown clinically | ||
| 520 | |a OBJECTIVE: Here, we reviewed the potential effects of these agents on platelet function in diabetes | ||
| 520 | |a RESULTS AND CONCLUSION: GLP-1RA and DPP-4i drugs have antiplatelet properties beyond their primary hypoglycemic effects. Whilst we have little direct evidence for the antiplatelet effects of SGLT2 inhibitors, some studies have shown that these agents may inhibit platelet aggregation and reduce the risk of thrombotic events in diabetes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Sodium-glucose cotransporter 2 inhibitors | |
| 650 | 4 | |a anti-diabetic drugs | |
| 650 | 4 | |a cardiovascular | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a dipeptidyl peptidase-4 inhibitors | |
| 650 | 4 | |a glucagon like peptide-1 receptor agonists | |
| 650 | 4 | |a platelet | |
| 650 | 4 | |a thrombosis. | |
| 650 | 7 | |a Dipeptidyl-Peptidase IV Inhibitors |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Sodium-Glucose Transporter 2 Inhibitors |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
| 650 | 7 | |a 89750-14-1 |2 NLM | |
| 700 | 1 | |a Atkin, Stephen L |e verfasserin |4 aut | |
| 700 | 1 | |a Jamialahmadi, Tannaz |e verfasserin |4 aut | |
| 700 | 1 | |a Sahebkar, Amirhossein |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine, metabolic & immune disorders drug targets |d 2006 |g 20(2020), 3 vom: 26., Seite 328-334 |w (DE-627)NLM161976174 |x 2212-3873 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:3 |g day:26 |g pages:328-334 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871530319666191014110414 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 3 |b 26 |h 328-334 | ||